Identification of new diagnostic and prognostic markers and therapy targets



    In Austria as in Western industrialized countries about one in ten men is confronted with the diagnosis prostate cancer during his lifetime. It is the most common male cancer and the second leading cause of cancer deaths in men. The most important risk factor is age and with continued increase of life expectancy this health problem will further gain importance. Considerable effort are put into early detection, since only patients with early-stage, organ-confined tumors can be cured. Starting from the tumor Biobank collection of serum samples and tissue specimens set up in the Tyrolean screening program our proposed project aims at identifying new markers to improve early detection of prostate cancer and to better predict tumor behaviour in order to select optimal treatment and to pave the way for individualized patient care. Furthermore, we plan to identify and test new therapy targets. We will apply new protein profiling techniques (proteomics) to identify unique signatures of prostate cancer and the different stages of the disease. New markers and targets will be identified and characterised in terms of expression patterns and function. In addition, we aim at developing high-throughput assays and test their clinical application, and establish novel therapy concepts targeting the identified proteins.

    Employing complementary methods we will establish proteome profiles of serum and tissue samples of prostate cancer and controls. The starting point of the study is the Biobank of the Department of Urology containing serum samples from the Tyrol PSA screening program for the early detection of prostate cancer and frozen and paraffin tissue specimens from patients who underwent radical prostatectomy. The Biobank links information on the stored samples to patients’ data, laboratory values, histopathology results and follow-up after treatment. Using bioinformatics tools the profiles will be analyzed and signatures established that discriminate between patients with cancer or malignant conditions, and between tumors of different stages and aggressiveness/progression potential. Data mining tools will be applied for identifying new markers for diagnosis and prognosis of prostate cancer and potential new therapy targets. Structural analysis will identify the molecules behind the marker peaks, and, in combination with bioinformatics, provide information about their structural features and functional properties. For the most promising of these markers and therapy targets expression and function will be investigated and subsequently high-throughput assays developed and tested. Finally retrospective and prospective studies will determine how introduction of these new markers can improve early prostate cancer diagnosis and prediction of the risk of progression.

    Development of diagnostic and prognostic markers and new therapy targets for advancing patienttailored
    tumor therapy of prostate cancer.
    • Complementary new proteomics profiling techniques for identification of markers and targets
    • Identification of markers by development and applying data mining tools linking proteomics
    profiles with patients data disease characteristics, treatment and outcome
    • Identification, characterization, structural analysis and validation of a set of markers with
    highest discriminating power for early detection and assessment of risk of progression
    • Development and testing of determination methods and high throughput techniques for
    marker measurements
    • Testing clinical application of identified markers and development of new therapy concepts
    KurztitelProstate Cancer Proteomics (ProCaP)
    Tatsächlicher Beginn/ -es Ende1/04/0631/03/09

    Systematik der Wissenschaftszweige 2002

    • 1409 Humanbiologie
    • 1411 Molekularbiologie
    • 1403 Biophysik
    • 1402 Biochemie